
In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient eligibility. Prof Subklewe advocates for structured referral pathways and multidisciplinary boards that assess all eligible patients in collaboration with CAR T-cell experts. She argues that treatment eligibility should not depend solely on individual physicians and highlights the benefits of coordinated networks, shared decision-making, professional education, and patient engagement. Listen now for insights into how stronger referral systems could help more patients access CAR T-cell therapy across Europe.This podcast episode is supported by Bristol Myers Squibb. Guests: Prof Marion SubkleweAffiliation: LMU – University Hospital, LMU Munich Department of Hematology/Oncology LMU- Gene Center Munich Laboratory of Translational Cancer Immunology Germany Host: Isabel Olivera-Martínez, PhD, EHA Medical WriterLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award

Improving MPNs management: EHA2026 Lifetime Achievement Award

CAR T Toxicities in Focus: What We Have Learned from Registry Data

Life After YERM: How the Young EHA Research Meeting Shaped Careers
Free AI-powered recaps of EHA Unplugged and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.